Orphan drug applications skyrocket as Big Pharma carves out niches

01/31/2013 | Wall Street Journal, The

Rare diseases are getting renewed interest from drugmakers attracted to an easier path toward FDA approval and high prices for orphan drugs. Large companies are working on or have already secured approval for drugs that treat rare conditions. Progress in understanding the molecular workings of disease has also spurred drugmakers' interest.

View Full Article in:

Wall Street Journal, The